Genenta (GNTA) director granted 20,000 options vesting from 2026

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Genenta Science S.p.A. director Mutti Miguel Maria received a grant of stock options covering 20,000 American Depositary Shares. The options were granted at no cost, with an exercise price of $0.63 per share and an expiration date of December 31, 2035.

The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the director’s compensation with longer-term company performance. Following this grant, the director holds 20,000 stock options directly, with no open-market share purchases or sales reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mutti Miguel Maria

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Options granted: 20,000 options Exercise price: $0.63 per share Grant cost: $0.00 per option +3 more

6 metrics

Options granted 20,000 options Stock Option (right to buy) covering American Depositary Shares

Exercise price $0.63 per share Exercise price for the 20,000 GNTA American Depositary Shares

Grant cost $0.00 per option Options granted at no cost to the director

Total options after transaction 20,000 options Director’s derivative holdings following the grant

Option expiration December 31, 2035 Final date to exercise the GNTA stock options

Vesting start date March 30, 2026 Monthly vesting over one year beginning this date

Key Terms

Stock Option (right to buy), American Depositary Shares, exercise price, Grant, award, or other acquisition, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

American Depositary Shares financial

"underlying_security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

exercise price financial

"conversion_or_exercise_price: "0.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest in equal monthly installments financial

"The stock options vest in equal monthly installments over one year"

Form 4 Insider Transactions: What Each Field Means →

04/01/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mutti Miguel Maria

(Last)

(First)

(Middle)

GIEBELWEG 5

(Street)

BUONAS ZUG

6343

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Genenta Science S.p.A. [ GNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.63	03/30/2026		A		20,000		⁽¹⁾	12/31/2035	American Depositary Shares	20,000	$0	20,000	D

Explanation of Responses:

1. The stock options vest in equal monthly installments over one year beginning March 30, 2026.

	/s/ Miguel Maria Mutti	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did GNTA director Mutti Miguel Maria report?

The director reported receiving a grant of stock options for 20,000 American Depositary Shares. These options are a compensation award, not an open-market purchase or sale, and give the right to buy GNTA ADS at a fixed exercise price in the future.

What is the exercise price of the new Genenta (GNTA) stock options?

The granted stock options have an exercise price of $0.63 per American Depositary Share. This means the director can buy up to 20,000 GNTA ADS at $0.63 each once vested, regardless of the future market price at exercise time.

How do the newly granted GNTA stock options vest over time?

The 20,000 stock options vest in equal monthly installments over one year beginning March 30, 2026. This monthly vesting schedule gradually delivers exercisable options, encouraging ongoing service and alignment with Genenta’s longer-term performance over that 12‑month period.

When do the Genenta (GNTA) stock options granted to the director expire?

The stock options expire on December 31, 2035, if not exercised earlier. After this expiration date, any unexercised options become worthless, so the director must exercise vested options before then to acquire Genenta American Depositary Shares at the $0.63 exercise price.

Did the GNTA director buy or sell any shares on the open market in this filing?

No open-market purchases or sales were reported in this filing. The Form 4 only shows a compensation-related grant of stock options for 20,000 American Depositary Shares, awarded at no cost with a $0.63 exercise price and future vesting requirements.